ClearNote Health’s Avantect® Pancreatic Cancer Test Now Available to Health Plan Members Accessing Claritev’s National PPO Networks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2025
0mins
Should l Buy ?
Source: Businesswire
Partnership Announcement: ClearNote Health has partnered with Claritev, Inc. to make its Avantect® Pancreatic Cancer Test available to health plan members through Claritev’s networks, aiming to improve early detection of pancreatic cancer in high-risk patients.
Innovative Testing Technology: The Avantect test utilizes a DNA-based blood analysis and advanced AI algorithms to detect early signs of pancreatic cancer, significantly enhancing the chances of successful treatment for patients diagnosed at an earlier stage.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
